Trial Profile
Efficacy, Safety Profiles and Cost-effectiveness Analysis of Pegfilgrastim and Lenograstim in Patients with Non Metastatic Breast Cancer Receiving Adjuvant Myelosuppressive Chemotherapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2012
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Lenograstim
- Indications Febrile neutropenia; Neutropenia
- Focus Therapeutic Use
- 17 Apr 2012 New trial record
- 24 Mar 2012 To date 20 patients have been enrolled